Phase III Study of ATL-962 in Obese Patients
Phase 3
- Conditions
- Obesity
- Registration Number
- JPRN-jRCT2080221428
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Inpatient/outpatient during the run-in period: Outpatient
The subject can read and understand the written information/consent form and can give his/her consent to participate in this study.
Exclusion Criteria
The subject has a serious heart disease, a cerebrovascular disease or a serious disease of the pancreas or blood.
The subject has been determined to be ineligible by the investigator or subinvestigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method